

Contents

Preface to the first edition — VII

Preface to the second edition — XI

How to study pharmaceutical chemistry effectively — XIII

How to achieve success in exams: some specific hints for pharmaceutical chemistry — XV

About the author — XXIII

1 Basic concepts in pharmaceutical chemistry — 1

- 1.1 Goals — 1
- 1.2 Basic concepts and purposes of pharmaceutical chemistry — 1
- 1.3 Historical development of pharmaceutical chemistry — 4
 - 1.3.1 Pre-scientific period (~ 3000 years BC until the nineteenth century) — 4
 - 1.3.2 Scientific period (nineteenth century to 1960) — 4
 - 1.3.3 Current period (from the 1960s to the present) — 5
- 1.4 Multidisciplinary nature of this discipline — 5
- 1.5 Patents — 6
 - 1.5.1 Cahn–Ingold–Prelog priority rules — 7
 - 1.5.2 Importance of homochiral drug development — 8
 - 1.5.2.1 The thalidomide tragedy — 8
- 1.6 Origin of drugs — 9
- 1.7 Other definitions — 10
- 1.8 Classification of drugs — 10
- 1.9 Process of discovery of a drug — 11
- 1.10 Phases of clinical studies — 12
- 1.11 Key notes: introduction — 12
- 1.12 Key notes: clinical trials — 13

2 Drug nomenclature — 14

- 2.1 Goals — 14
- 2.2 Introduction — 14
- 2.3 Nomenclature of drugs — 14
- 2.4 Systematic chemical names — 15
- 2.5 Polyfunctional acyclic compounds — 16
- 2.6 Monocyclic compounds — 18
- 2.7 Polycyclic aromatic hydrocarbons — 20

2.8	Partly or fully hydrogenated polycyclic hydrocarbons —	22
2.9	Bicyclic hydrocarbons —	23
2.9.1	Bridge systems —	23
2.9.2	Bicyclic systems with heteroatoms —	24
2.9.3	Spiro or spirane systems —	26
2.10	Heterocycles —	27
2.10.1	Condensed heterocycles —	30
2.11	Numbering of condensed heterocycles —	32
2.12	Criteria for choosing the base heterocycle —	33
2.13	Heterocycles condensed with benzene —	35
2.14	Exercises —	37
3	Search for prototypes —	42
3.1	Goals —	42
3.2	Traditional and current discovery of new drugs —	42
3.2.1	Screening of natural products —	43
3.2.2	Existing drugs used as leaders —	45
3.2.3	Isolation and identification of drug metabolites —	46
3.2.4	Examples of serendipity —	47
3.3	Planned syntheses of new chemical compounds on rational bases —	49
3.4	Isolation and purification —	50
3.5	Structural determination —	50
3.6	Key notes —	51
3.7	A pitfall —	51
4	Optimization of prototypes —	52
4.1	Goals —	52
4.2	Molecular modification —	52
4.2.1	Purpose —	52
4.2.1.1	Development of substitutes and therapeutic copies —	52
4.2.1.2	Development of drugs with different spectrum of action —	54
4.2.1.3	Modification of pharmacokinetics —	55
4.2.1.4	Modification of distribution —	55
4.3	Strategies —	56
4.3.1	Modulative structural variation —	57
4.3.1.1	Vinylogy —	57
4.3.1.2	Homology —	59
4.3.1.3	Introduction of cyclic systems —	59
4.3.1.4	Introduction or substitution of polar groups, by nonpolar bulky ones —	60
4.3.1.5	Isosterism and bioisosterism —	60
4.3.1.5.1	Isosterism —	60

- 4.3.1.5.2 Bioisosterism — 63
- 4.4 Disjunctive replication — 69
- 4.5 Conjunctive replication — 70
- 4.6 Peptidomimetics — 71
- 4.7 Summary — 71
- 4.8 Exercises — 73

5 Biological targets and receptors for drugs — 82

- 5.1 Goals — 82
- 5.2 Membrane receptor — 82
- 5.3 Affinity and intrinsic activity: agonists and antagonists — 83
- 5.4 Types of receptors — 83
 - 5.4.1 Ionic channels — 83
 - 5.4.2 Receptors with an intrinsic catalytic activity — 84
 - 5.4.3 Receptors bound to G proteins: metabotropic receptors — 85
 - 5.4.3.1 Guanosine diphosphate — 85
 - 5.4.4 Intracellular receptors — 88
- 5.5 Types of bonds: energy range (kcal/mol) per interaction — 89
 - 5.5.1 Intramolecular bonding interactions — 89
 - 5.5.2 Intermolecular interactions — 90
- 5.6 Conformation and activity: use of rigid analogs — 94
 - 5.6.1 Nomenclature of conformations (Newman projections) — 94
- 5.7 Absolute configuration and activity: difference between enantiomers — 99
- 5.8 Relative configuration and activity — 100
- 5.9 Key notes: receptors — 103
- 5.10 Key notes: binding interactions — 103
- 5.11 Key notes: stereochemistry — 103
- 5.12 Exercises — 104

6 Quantitative drug design: parameters and quantitative structure-activity relationships — 110

- 6.1 Goals — 110
- 6.2 Introduction — 110
- 6.3 Electronic parameters — 112
 - 6.3.1 Interpretation of Hammett constants — 113
 - 6.3.1.1 Electronic effects — 113
- 6.4 Substituents classified according to their directing power in electrophilic aromatic reactions — 116
- 6.5 Hyperconjugation — 117
 - 6.5.1 Electronegativity of an sp^n hybrid orbital — 117

6.5.2	Activating effect of the toluene methyl group versus S_EAr reactions — 118
6.5.3	Difference between hyperconjugation and resonance — 119
6.6	Hydrophobic parameters: partition coefficient and hydrophobic substituent constant — 119
6.7	Steric parameters — 122
6.8	Craig plot — 122
6.9	Hansch equation — 123
6.10	Concepts and QSAR philosophy — 125
6.11	3D QSAR model — 125
6.12	CoMFA advantages over traditional QSAR — 126
6.13	Potential problems of CoMFA — 127
6.14	Key notes: quantitative structure–activity relationships — 128
6.15	The significance of QSAR in drug discovery — 128
6.16	Exercises — 129
7	Metabolic processes in drugs: other methodologies available for the discovery of new drugs — 135
7.1	Goals — 135
7.2	Metabolism studies and their use in the discovery of new drugs — 135
7.3	Absorption — 135
7.4	Lipinski's rules (rule of 5) — 137
7.5	Metabolism — 137
7.5.1	Phase I reactions — 139
7.5.1.1	Oxidation reactions — 139
7.5.1.2	Reduction reactions — 142
7.5.1.3	Hydrolysis reactions — 142
7.5.2	Phase II reactions — 143
7.5.2.1	Conjugation reactions — 143
7.5.2.1.1	The anomeric effect — 143
7.5.2.2	Glucuronides — 149
7.5.2.3	Conjugation with glycine — 149
7.5.2.4	Acetylation — 151
7.5.2.5	Conjugation reactions with glutathione — 151
7.6	Prodrug concept — 154
7.6.1	Improvements in the galenic formulations — 154
7.6.2	Pharmacokinetic improvements — 155
7.7	Modulation of drug metabolism — 156
7.8	Suppression of the metabolic processes — 157
7.9	Promotion of the nonoxidative metabolism — 158

7.10	Summary —	159
7.11	Key notes: drug metabolism —	160
7.12	Exercises —	161
8	Synthetic drug strategies —	165
8.1	Goals —	165
8.2	Introduction —	165
8.3	Definitions —	166
8.4	Rules to make a good disconnection —	167
8.5	<i>endo</i> selectivity —	169
8.6	Synthesis of various barbiturates —	170
8.6.1	Pentobarbital —	170
8.6.2	Phenobarbital —	170
8.6.3	Hexobarbital —	172
8.7	Buprenorphine —	172
8.8	Celecoxib —	173
8.9	Rofecoxib —	175
8.10	Fentanyl —	176
8.11	Electrophilic substitution on pyrroles —	177
8.12	Exercises —	180
9	Solutions to the exercises —	181
9.1	Exercises to Chapter 2 —	181
9.2	Exercises to Chapter 4 —	184
9.3	Exercises to Chapter 5 —	185
9.4	Exercises to Chapter 6 —	193
9.5	Exercises to Chapter 7 —	197
9.6	Exercises to Chapter 8 —	205
Index —		213